Previous Page  5 / 5
Information
Show Menu
Previous Page 5 / 5
Page Background

Journal of Clinical Immunology and Allergy

ISSN: 2471-304X

Page 25

16

th

EuroSciCon Conference on Immunology

March 11-12, 2019 | Amsterdam, Netherlands

Immunology 2019

I

n vivo efficacy evaluation has always been a rate-limiting step during

therapeutic antibody discovery due to species specificity. Using gene-

editing technology, we have generated and functionally validated a series

of single and double humanized mouse models for the I/O field such as

B-hPD-1/hPD-L1, B-CTLA-4, B-hOX-40, B-hCD47/h-SIRPa and B-hCD3e.

Thesemodels are very useful not only for single agent treatment, but also for

combination therapy and bispecific antibody development.

Novel I-O Drug Discoveries Empowered

by Humanized Animal Models

Yi Yang

Biocytogen, China

Biography

Dr. Yi (Benny) Yang received his Ph.D. degree in

immunology from University of Connecticut and

completed his postdoctoral training in New York

University at Dr. Dan R. Littman’s group. Dr. Yang

was a tenure-track Assistant Professor at Medical

University of South Carolina from 2014 to 2016 and

joined Biocytogen in 2016. He studied the newly

discovered immune regulation of Th17 cells and

intestinal microbial immunity, and published a series

of paper on Nature, Science and Cell.

info@biocytogen.com

Yi Yang, J Clin Immunol Allergy 2019, Volume:5

DOI: 10.21767/2471-304X-C1-007